BioNTech Company Insiders

BioNTech's latest congressional trading

BioNTech Management Team Effectiveness

The company has return on total asset (ROA) of 0.0262 % which means that it generated a profit of $0.0262 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0462 %, meaning that it created $0.0462 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Return On Capital Employed is likely to drop 0.03 in 2024. At this time, BioNTech's Fixed Asset Turnover is fairly stable compared to the past year. Return On Assets is likely to rise to 0.07 in 2024, whereas Debt To Assets are likely to drop 0.01 in 2024. Net Income Applicable To Common Shares is likely to rise to about 12.4 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 229.1 M in 2024.

BioNTech Workforce Comparison

The company has Profit Margin (PM) of 0.24 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.4 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.4.

BioNTech SE Benchmark Summation

BioNTech Notable Stakeholders

The success or failure of an entity such as BioNTech SE often depends on how effective the management is. BioNTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioNTech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioNTech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in BioNTech's official financial statements usually reflect BioNTech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of BioNTech SE. For example, before you start analyzing numbers published by BioNTech accountants, it's critical to develop an understanding of what BioNTech's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.

Please note, the presentation of BioNTech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioNTech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in BioNTech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioNTech SE. Please utilize our Beneish M Score to check the likelihood of BioNTech's management manipulating its earnings.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.